NDAINHALATIONGAS
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
HELIUM, USP (helium) by Advanced Solutions Life Sciences. Approved for aortic valve stenosis, asthma, obesity and 1 more indications. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELIUM, USP is an inhaled gas product approved in 2019 for treating aortic valve stenosis, asthma, obesity, and metabolic syndrome. The mechanism of action and pharmacologic class are not specified in regulatory documentation. Patients inhale this gaseous formulation as a therapeutic intervention across multiple cardiovascular and metabolic indications.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30/100); team size and resource allocation likely stable but constrained by lack of breakthrough differentiation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.